ProCE Banner Activity

Novel Therapies for Psoriasis Care: Targeting the JAK-STAT Pathway

Clinical Thought

This expert commentary explores the therapeutic approach of targeting the JAK-STAT pathway in the management of moderate to severe psoriasis, with an evidence-based focus on new and emerging JAK and TYK2 inhibitors.

Released: December 20, 2022

Expiration: December 19, 2023

No longer available for credit.



Steven Feldman

Steven Feldman, MD, PhD

Professor of Dermatology, Pathology and Social Sciences & Health Policy
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Provided by

ProCE Banner


This activity is supported by an educational grant from

Bristol Myers Squibb